SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals

被引：0
|
作者：
Kelin She
Shenghua Fang
Wei Du
Xingxing Fan
Jiaxi He
Hui Pan
Liyan Huang
Ping He
Jun Huang
机构：
[1] The First Affiliated Hospital of Guangzhou Medical University,Department of Thoracic Surgery
[2] Guangzhou Research Institute of Respiratory Disease,Department of Thoracic Surgery
[3] China Key Laboratory of Respiratory Disease,Department of Pathology
[4] National Center for Clinical Trials on Respiratory Diseases,undefined
[5] The Central Hospital of Shaoyang City,undefined
[6] Affiliated Cancer Hospital & Institute of Guangzhou Medical University,undefined
[7] Dongguan People’s Hospital,undefined
[8] State Key Laboratory of Quality Research in Chinese Medicine,undefined
[9] Macau Institute for Applied Research in Medicine and Health,undefined
[10] Macau University of Science and Technology,undefined
[11] The First Affiliated Hospital of Guangzhou Medical University,undefined
来源：
Cancer Cell International | / 19卷
关键词：
SCD1; EGFR; AKT; EMT; Lung cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals
    She, Kelin
    Fang, Shenghua
    Du, Wei
    Fan, Xingxing
    He, Jiaxi
    Pan, Hui
    Huang, Liyan
    He, Ping
    Huang, Jun
    CANCER CELL INTERNATIONAL, 2019, 19 (1)
  • [2] Saikosaponin-A Exhibits Antipancreatic Cancer Activity by Targeting the EGFR/PI3K/Akt Pathway
    Shi, Chengda
    Sun, Linglin
    Fang, Rong
    Zheng, Shuying
    Yu, Mingming
    Li, Qiang
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2023, 24 (04) : 579 - 588
  • [3] Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
    Carpenter, Richard L.
    Jiang, Bing-Hua
    CURRENT CANCER DRUG TARGETS, 2013, 13 (03) : 252 - 266
  • [4] Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
    Bang, Jieun
    Jun, Mihyeon
    Lee, Soyun
    Moon, Hyuk
    Ro, Simon Weonsang
    PHARMACEUTICS, 2023, 15 (08)
  • [5] Targeting PI3K/Akt signaling in prostate cancer therapy
    Hashemi, Mehrdad
    Taheriazam, Afshin
    Daneii, Pouria
    Hassanpour, Aria
    Kakavand, Amirabbas
    Rezaei, Shamin
    Hejazi, Elahe Sadat
    Aboutalebi, Maryam
    Gholamrezaie, Hamidreza
    Saebfar, Hamidreza
    Salimimoghadam, Shokooh
    Mirzaei, Sepideh
    Entezari, Maliheh
    Samarghandian, Saeed
    JOURNAL OF CELL COMMUNICATION AND SIGNALING, 2023, 17 (03) : 423 - 443
  • [6] Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
    Novoplansky, Ofra
    Shnerb, Avital B.
    Marripati, Divyasree
    Jagadeeshan, Sankar
    Abu Shareb, Raghda
    Conde-Lopez, Cristina
    Zorea, Jonathan
    Prasad, Manu
    Ben Lulu, Talal
    Yegodayev, Ksenia M.
    Benafsha, Chen
    Li, Yushi
    Kong, Dexin
    Kuo, Fengshen
    Morris, Luc G. T.
    Kurth, Ina
    Hess, Jochen
    Elkabets, Moshe
    MOLECULAR ONCOLOGY, 2023, : 2618 - 2636
  • [7] Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway
    Ganesan, Kumar
    Xu, Cong
    Wu, Jianming
    Du, Bing
    Liu, Qingqing
    Sui, Yue
    Song, Cailu
    Zhang, Jinhui
    Tang, Hailin
    Chen, Jianping
    SCIENCE CHINA-LIFE SCIENCES, 2024, 67 (09) : 1849 - 1866
  • [8] γ Secretase Inhibitor BMS-708163 Reverses Resistance to EGFR Inhibitor via the PI3K/Akt Pathway in Lung Cancer
    Xie, Mian
    He, Jianxing
    He, Chaosheng
    Wei, Shenhai
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2015, 116 (06) : 1019 - 1027
  • [9] Activation of EGFR-PI3K-AKT signaling is required for Mycoplasma hyorhinis-promoted gastric cancer cell migration
    Duan, Hongying
    Qu, Like
    Shou, Chengchao
    CANCER CELL INTERNATIONAL, 2014, 14
  • [10] miRNA-223 is an anticancer gene in human non-small cell lung cancer through the PI3K/AKT pathway by targeting EGFR
    Ma, Hui-Ping
    Kong, Wei-Xiang
    Li, Xiu-Ying
    Li, Wei
    Zhang, Yan
    Wu, Yan
    ONCOLOGY REPORTS, 2019, 41 (03) : 1549 - 1559
12345